triazoles has been researched along with sirolimus in 60 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 19 (31.67) | 29.6817 |
2010's | 39 (65.00) | 24.3611 |
2020's | 2 (3.33) | 2.80 |
Authors | Studies |
---|---|
Ellis, M | 1 |
Friedman, GS; Mathis, AS; Shah, NK | 1 |
Azanza, JR; Campanero, MA; Quetglas, EG; Sádaba, B | 1 |
Boulay, A; Chen, S; Evans, DB; Lane, HA; O'Reilly, T; Rudloff, J; Ye, J; Zumstein-Mecker, S | 1 |
Antin, JH; Baden, LR; Campbell, BJ; Cutler, CS; Fiumara, K; Lowry, CM; Marty, FM | 1 |
Lane, HA; Lebwohl, D | 1 |
Abrial, C; Chollet, P; Curé, H; Durando, X; Leheurteur, M; Mouret-Reynier, MA; Tacca, O | 1 |
Beeram, M; DeGraffenried, LA; Middleton, A; Russell, D; Tan, QT; Tekmal, RR | 1 |
Book, BK; Lemonte, A; Pescovitz, MD; Smedema, M; Wheat, LJ; Zhuang, D | 1 |
Awada, A; Cardoso, F; De Grève, J; Dirix, L; Fontaine, C; Piccart, M; Sotiriou, C; Steinseifer, J; Tanaka, C; Tang, P; Wouters, C; Zoellner, U | 1 |
Collingridge, D | 1 |
Carver, PL; DePestel, DD; Surowiec, D | 1 |
Hussar, DA | 2 |
Adani, GL; Baccarani, U; Baraldo, M; Cojutti, P; Franceschi, L; Furlanut, M; Londero, A; Pea, F; Tavio, M; Viale, P | 1 |
Fricker, J | 1 |
Krishna, G; Ma, L; Martinho, M; McLeod, J; Moton, A; Seiberling, M | 1 |
Baselga, J; Bellet, M; Bianchi, G; Campone, M; Dixon, JM; Gardner, H; Greil, R; Jonat, W; Kubista, E; Lane, HA; Manikhas, A; Mayordomo, J; Molloy, B; Phillips, P; Rugo, HS; Semiglazov, V; Steinseifer, J; Stumm, M; Tokaji, E; van Dam, P | 1 |
Dannaoui, E; Lortholary, O; Schwarz, P | 1 |
Abboud, I; Antoine, C; Benammar, M; Berge, M; Billaud, EM; Glotz, D; Lefeuvre, S | 1 |
Alangaden, GJ; Chandrasekar, PH; Manavathu, E; Narreddy, S; Revankar, SG | 1 |
Dixit, NM; Mulampaka, SN | 1 |
Brown, M; O'Reilly Zwald, F | 1 |
Ancochea, J; Casanova, A | 1 |
de Azambuja, E; Metzger-Filho, O | 1 |
Airoud, K; Alfieri, RR; Andreis, D; Bertoni, R; Bonelli, MA; Bottini, A; Cavazzoni, A; Fumarola, C; Galetti, M; Galvani, E; Generali, D; Harris, AL; La Monica, S; Martin, LA; Petronini, PG; Tramonti, S | 1 |
Bhandaru, M; Bobbala, D; Lang, F; Pasham, V; Rotte, A; Zelenak, C | 1 |
Antin, JH; Armand, P; Baden, LR; Hammond, SP; Koo, S; Kubiak, DW; Marty, FM | 1 |
Ito, Y | 1 |
A'Hern, R; Dowsett, M; Evans, DB; Farmer, I; Ghazoui, Z; Guest, S; Johnston, SR; Lane, HA; Martin, LA; Pancholi, S; Ribas, R; Thornhill, AM; Weigel, MT | 1 |
De, G; Diener, M; Namjoshi, M; Wu, EQ; Xie, J; Yang, H | 1 |
Berkenblit, A; Bondarenko, I; Brincat, S; Chan, A; Chow, L; Cincotta, M; Fumoleau, P; Garin, AM; Guimaraes, RC; Hachemi, S; Hayes, DF; Kang, LL; Krygowski, M; Lazar, AA; Moore, L; Neskovic-Konstantinovic, Z; Strahs, A; Sun, Y; Wolff, AC | 1 |
Bartlett, JM; Baselga, J; Dixon, JM; Loi, S; Michiels, S; Piccart, MJ; Sabine, VS; Sahmoud, T; Sims, AH; Singhal, SK; Sotiriou, C | 1 |
Bachelot, T; Ben Larbi, S; Cohen, PA; Corbo, L; Ghayad, SE; Grisard, E; Heudel, PE; Treilleux, I; Vendrell, JA; Villedieu, M; Vilquin, P | 1 |
Hou, G; Liu, J; Liu, Y; Zhang, J; Zhang, S; Zhang, X | 1 |
Mehta, A; Tripathy, D | 1 |
Atkins, JT; Falchook, GS; Fu, S; Hong, DS; Janku, F; Kurzrock, R; Moulder, SL; Naing, A; Piha-Paul, SA; Stephens, PJ; Tsimberidou, AM; Wheler, JJ; Yelensky, R; Zinner, R | 1 |
Fung, HC; Peksa, GD; Schultz, K | 1 |
Lu, XY; Xu, H; Yang, Y; Zeng, T; Zhang, ZZ | 1 |
Bradner, JE; Doan, NB; Forscher, C; Koeffler, HP; Lee, DH; Qi, J; Said, JW; Yang, H | 1 |
Brown, MP; Singhal, N; Vatandoust, S | 1 |
Bachelot, T; Barrios, C; de Boer, R; Di Leo, A; Janni, W; Jerusalem, G; Neven, P | 1 |
Coleman, RL; Gershenson, DM; Jiang, Y; Johnston, T; Levenback, C; Lu, KH; Munsell, MF; Nowakowski, M; Ring, K; Slomovitz, BM; Soliman, PT; Yates, MS; Zhang, Q | 1 |
Chan, H; Cho, E; Nakamura, R; Nguyen, HM; Pon, D; Shayani, S | 1 |
Bogani, G; Chiappa, V; Lorusso, D; Raspagliesi, F | 1 |
Coleman, RL; Slomovitz, BM | 1 |
Bozhok, AA; Dashyan, GA; Komyakhov, AV; Lalak, IA; Manikhas, AG; Paltuev, RM; Petrenko, OL; Semiglazov, VF; Semiglazov, VV; Semiglazova, TY | 1 |
Furukawa, S; Handa, H; Hashimoto, A; Hashimoto, S; Mikami, S; Oikawa, T; Okada, Y; Onodera, Y; Oya, M; Sabe, H; Sugino, H; Yoshikawa, A | 1 |
Deyo, JC; Kozlowski, T; Lachiewicz, A; Nicolsen, N | 1 |
Assanelli, A; Barbanti, MC; Bernardi, M; Carrabba, M; Ciceri, F; Corti, C; Forcina, A; Giglio, F; Greco, R; Lupo Stranghellini, MT; Marktel, S; Messina, C; Morelli, M; Oltolini, C; Peccatori, J; Piemontese, S; Scarpellini, P; Vago, L | 1 |
Chen, X; Cheng, Y; Huang, J; Li, K; Lv, Y; Pan, F; Xie, L; Yang, D; Ying, J; Yu, H | 1 |
Akhtar, S; Desai, A; Groll, AH; Han, D; Howieson, C; Kato, K; Kowalski, D; Lademacher, C; Lewis, W; Mandarino, D; Pearlman, H; Townsend, R; Yamazaki, T | 1 |
Jung, I; Koš, M; Kos-Braun, IC | 1 |
Chen, G; Gong, S; Guo, LW; Kent, KC; Shi, X; Urabe, G; Wang, B; Wang, Y; Xie, R | 1 |
Dadwal, S; Jhangiani, K; Kieu, V; Nakamura, R; Pon, D | 1 |
Chen, X; Cheng, Y; Huang, J; Huang, Q; Huang, X; Lv, Y; Xie, L; Ying, J; Yu, H; Zheng, C | 1 |
Kim, DU; Kim, SW; Kwak, B | 1 |
Dannaoui, E; Felske-Zech, H; Schwarz, P; Schwarz, PV | 1 |
Alexander, G; Challagundla, KB; Chaturvedi, NK; Coulter, DW; Griggs, CN; Joshi, SS; Kling, MJ; McIntyre, EM; Ray, S | 1 |
Gao, L; Sun, Y; Tan, L; Yang, J; Yao, Z; Zeng, T | 1 |
7 review(s) available for triazoles and sirolimus
Article | Year |
---|---|
Overcoming endocrine therapy resistance by signal transduction inhibition.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Farnesyltranstransferase; Humans; Immunosuppressive Agents; Letrozole; Nitriles; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Tamoxifen; Triazoles | 2004 |
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Everolimus; Female; Forecasting; Humans; Immunosuppressive Agents; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Sirolimus; Triazoles | 2006 |
Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients.
Topics: Carcinoma, Basal Cell; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Education, Medical, Continuing; Female; Humans; Immunocompromised Host; Incidence; Male; Melanoma; Organ Transplantation; Prognosis; Pyrimidines; Risk Assessment; Sarcoma, Kaposi; Sirolimus; Skin Neoplasms; Survival Analysis; Treatment Outcome; Triazoles; Voriconazole | 2011 |
[Progress of molecularly targeted therapy for breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Denosumab; Drug Design; Drug Therapy, Combination; Everolimus; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2012 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Nitriles; Patient Selection; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Failure; Treatment Outcome; Triazoles | 2015 |
Salvage Treatment of Mucormycosis Post-Liver Transplant With Posaconazole During Sirolimus Maintenance Immunosuppression.
Topics: Antifungal Agents; Female; Humans; Immunosuppressive Agents; Liver Transplantation; Maintenance Chemotherapy; Middle Aged; Mucormycosis; Salvage Therapy; Sirolimus; Treatment Outcome; Triazoles | 2017 |
10 trial(s) available for triazoles and sirolimus
Article | Year |
---|---|
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Drug Interactions; Everolimus; Feasibility Studies; Female; Humans; Immunosuppressive Agents; Letrozole; Male; Middle Aged; Nitriles; Sirolimus; Treatment Outcome; Triazoles | 2008 |
Effects of oral posaconazole on the pharmacokinetics of sirolimus.
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Area Under Curve; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Reference Values; Sirolimus; Triazoles; Young Adult | 2009 |
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Cyclin D1; Double-Blind Method; Europe; Everolimus; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Mutation; Neoadjuvant Therapy; Nitriles; Palpation; Phosphatidylinositol 3-Kinases; Phosphorylation; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Ribosomal Protein S6 Kinases; Sirolimus; Time Factors; Treatment Outcome; Triazoles; United States | 2009 |
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Placebos; Postmenopause; Sirolimus; Treatment Outcome; Triazoles | 2013 |
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Everolimus; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Letrozole; Middle Aged; Mutation; Nitriles; Phosphatidylinositol 3-Kinases; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2013 |
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Genital Neoplasms, Female; Humans; Kaplan-Meier Estimate; Middle Aged; Nitriles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Triazoles; Young Adult | 2014 |
Phase II study evaluating efficacy and safety of everolimus with letrozole for management of advanced (unresectable or metastatic) non-small cell lung cancer after failure of platinum-based treatment: a preliminary analysis of toxicity.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Carcinoma, Non-Small-Cell Lung; Everolimus; Female; Humans; Letrozole; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Nitriles; Organoplatinum Compounds; Sirolimus; Smoking; Triazoles | 2015 |
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bayes Theorem; beta Catenin; Biomarkers, Tumor; Cohort Studies; Disease-Free Survival; DNA Mutational Analysis; Endometrial Neoplasms; Endometriosis; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Immunosuppressive Agents; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome; Triazoles | 2015 |
[BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Doxorubicin; Everolimus; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Nitriles; Paclitaxel; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Triazoles | 2015 |
Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults.
Topics: Adult; Area Under Curve; Cyclosporine; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Middle Aged; Mycophenolic Acid; Nitriles; Prednisolone; Pyridines; Sirolimus; Tacrolimus; Triazoles; Young Adult | 2017 |
43 other study(ies) available for triazoles and sirolimus
Article | Year |
---|---|
Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases.
Topics: Adult; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Candidiasis; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Lung Diseases, Fungal; Male; Middle Aged; Postoperative Complications; Pyrimidines; Sirolimus; Triazoles; Voriconazole | 2004 |
Clinical relevance of sirolimus drug interactions in transplant patients.
Topics: Aged; Antifungal Agents; Area Under Curve; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Heart Transplantation; Humans; Immunosuppressive Agents; Male; Pyrimidines; Sirolimus; Triazoles; Voriconazole | 2004 |
Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma; Cell Proliferation; Cell Survival; Drug Interactions; Estrogens; Everolimus; Female; Humans; Immunosuppressive Agents; Letrozole; Nitriles; Protein Kinases; Receptors, Estrogen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles; Tumor Cells, Cultured | 2005 |
Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Antifungal Agents; Cord Blood Stem Cell Transplantation; Creatinine; Dose-Response Relationship, Drug; Drug Evaluation; Drug Interactions; Female; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Leukemia; Lipids; Male; Middle Aged; Mycoses; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Pyrimidines; Retrospective Studies; Sirolimus; Transplantation, Homologous; Triazoles; Voriconazole | 2006 |
Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Nitriles; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Triazoles | 2006 |
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Flow Cytometry; Fulvestrant; Humans; Letrozole; Nitriles; Protein Kinases; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2007 |
Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay.
Topics: Antifungal Agents; Calcineurin Inhibitors; Cyclosporine; Drug Interactions; False Positive Reactions; Graft vs Host Disease; Humans; Immunosuppressive Agents; Microbiological Techniques; Sirolimus; Tacrolimus; Triazoles | 2008 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epothilones; Everolimus; Female; Fluorouracil; Humans; Letrozole; Nitriles; Sirolimus; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2008 |
Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management.
Topics: Antifungal Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Humans; Immunosuppressive Agents; Pilot Projects; Pyrimidines; Retrospective Studies; Sirolimus; Triazoles; Voriconazole | 2008 |
New drugs08, part 2.
Topics: Acromegaly; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Antineoplastic Agents; Biopterins; Carbapenems; Child; Child, Preschool; Cyclohexanes; Doripenem; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Epothilones; Humans; Infant; Maraviroc; Peptides, Cyclic; Pharmaceutical Preparations; Phenylketonurias; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sirolimus; Somatostatin; Triazoles | 2008 |
Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient.
Topics: Aged; Antifungal Agents; Aspergillosis; Drug Interactions; Everolimus; Fatal Outcome; Fluconazole; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Pyrimidines; Sirolimus; Triazoles; Voriconazole | 2008 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid | 2009 |
In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
Topics: Amphotericin B; Antifungal Agents; Azoles; Cyclosporine; Drug Interactions; Immunosuppressive Agents; Itraconazole; Microbial Sensitivity Tests; Mucorales; Rhizopus; Sirolimus; Tacrolimus; Thiazoles; Triazoles | 2009 |
Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient.
Topics: Antifungal Agents; Aspergillosis; Cytochrome P-450 CYP3A; Drug Interactions; Drug Monitoring; Everolimus; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Pyrimidines; Sirolimus; Triazoles; Voriconazole | 2009 |
New Drugs2010, PART 1.
Topics: Acetamides; Antibodies, Monoclonal; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Azepines; Benzazepines; Benzhydryl Compounds; Benzyl Alcohol; Benzylamines; Cyclams; Cyclopropanes; Drug Combinations; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Ethanolamines; Everolimus; Febuxostat; Fluorenes; Fluoroquinolones; Gout Suppressants; Heterocyclic Compounds; Humans; Immunosuppressive Agents; Indoles; Lacosamide; Milnacipran; Oligopeptides; Phenols; Selective Serotonin Reuptake Inhibitors; Sirolimus; Tapentadol; Thiazoles; Tolvaptan; Triazoles | 2010 |
In vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against zygomycetes.
Topics: Antifungal Agents; Calcineurin; Cyclosporine; Drug Interactions; Humans; Mucorales; Sirolimus; Tacrolimus; Triazoles | 2010 |
Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion.
Topics: CCR5 Receptor Antagonists; Clinical Trials, Phase III as Topic; Cloning, Molecular; Cyclohexanes; Down-Regulation; HIV Envelope Protein gp120; HIV-1; Humans; Maraviroc; Models, Biological; Piperazines; Protein Binding; Pyrimidines; Receptors, CCR5; Reproducibility of Results; Sirolimus; Triazoles; Virus Internalization | 2011 |
[Lymphangioleiomyomatosis: new therapeutic approaches].
Topics: Adult; Aromatase Inhibitors; Clinical Trials, Phase II as Topic; Doxycycline; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lung Neoplasms; Lung Transplantation; Lymphangioleiomyomatosis; Matrix Metalloproteinase Inhibitors; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Registries; Sirolimus; Spain; Therapies, Investigational; Triazoles | 2011 |
Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Repair; Drug Discovery; Everolimus; Female; Genetic Predisposition to Disease; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Neoadjuvant Therapy; Nitriles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Trastuzumab; Triazoles | 2011 |
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.
Topics: Aged; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Imidazoles; Immunosuppressive Agents; Letrozole; Neoadjuvant Therapy; Nitriles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2012 |
Rapamycin sensitive ROS formation and Na(+)/H(+) exchanger activity in dendritic cells.
Topics: Animals; Benzoxazoles; Cell Size; Cells, Cultured; Cyclic N-Oxides; Cytosol; Dendritic Cells; Enzyme-Linked Immunosorbent Assay; Escherichia coli; Flow Cytometry; Fluoresceins; Fluorescence; Hydrogen-Ion Concentration; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Reactive Oxygen Species; Sirolimus; Sodium-Hydrogen Exchangers; Spin Labels; tert-Butylhydroperoxide; Triazoles; Tumor Necrosis Factor-alpha | 2012 |
Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants.
Topics: Adult; Antifungal Agents; Drug Administration Schedule; Drug Dosage Calculations; Drug Synergism; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycoses; Sirolimus; Transplantation, Homologous; Triazoles | 2012 |
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Nucleolus; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Receptor, ErbB-3; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2012 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Budgets; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Everolimus; Female; Health Care Costs; Humans; Letrozole; Middle Aged; Nitriles; Receptor, ErbB-2; Severity of Illness Index; Sirolimus; Treatment Failure; Triazoles; United States | 2013 |
Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Estrogen Receptor alpha; Female; Heterocyclic Compounds, 3-Ring; Humans; MCF-7 Cells; Neoplasm Recurrence, Local; Nitriles; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2013 |
Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study.
Topics: Animals; Apoptosis; Aromatase; Breast Neoplasms; Cell Proliferation; Drug Synergism; Elafin; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; Mice; Nitriles; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2014 |
Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Algorithms; Antifungal Agents; Azoles; Drug Dosage Calculations; Female; Fluconazole; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycoses; Retrospective Studies; Sirolimus; Tacrolimus; Triazoles; Voriconazole; Young Adult | 2015 |
Synergistic in vitro anti-tumor effect of letrozole and everolimus on human endometrial carcinoma Ishikawa cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endometrial Neoplasms; Everolimus; Female; Humans; Letrozole; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoproteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2014 |
Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.
Topics: Animals; Apoptosis; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Core Binding Factor Alpha 1 Subunit; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Female; G1 Phase Cell Cycle Checkpoints; Genes, myc; Humans; Mice; Mice, Nude; Nuclear Proteins; Osteosarcoma; Sirolimus; Transcription Factors; Transcription Initiation Site; Triazoles; Xenograft Model Antitumor Assays | 2015 |
Management of drug interaction between posaconazole and sirolimus in patients who undergo hematopoietic stem cell transplant.
Topics: Adult; Aged; Antifungal Agents; Drug Interactions; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Sirolimus; Triazoles; Young Adult | 2015 |
Treatment of Recurrent Endometrial Carcinoma: Progress Toward a More Personalized Approach.
Topics: Endometrial Neoplasms; Female; Humans; Nitriles; Sirolimus; Triazoles | 2015 |
Reply to G. Bogani et al.
Topics: Endometrial Neoplasms; Female; Humans; Nitriles; Sirolimus; Triazoles | 2015 |
Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer.
Topics: ADP-Ribosylation Factor 6; ADP-Ribosylation Factors; Adult; Aged; Aged, 80 and over; Amides; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Female; GTP-Binding Protein alpha Subunits, G12-G13; Guanine Nucleotide Exchange Factors; HEK293 Cells; Humans; Immunohistochemistry; Indoles; Isoxazoles; Kidney Neoplasms; Lysophospholipids; Male; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Nerve Tissue Proteins; Propionates; Pyridines; Pyrroles; Receptors, Lysophosphatidic Acid; Signal Transduction; Sirolimus; Sunitinib; Triazoles | 2016 |
Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients.
Topics: Adolescent; Adult; Aged; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Remission Induction; Risk; Sirolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Triazoles; Young Adult | 2016 |
Synthesis of Rapamycin Derivatives Containing the Triazole Moiety Used as Potential mTOR-Targeted Anticancer Agents.
Topics: Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Targeted Therapy; Phosphorylation; Signal Transduction; Sirolimus; Structure-Activity Relationship; TOR Serine-Threonine Kinases; Triazoles | 2016 |
Tor1 and CK2 kinases control a switch between alternative ribosome biogenesis pathways in a growth-dependent manner.
Topics: Casein Kinase II; Heat-Shock Response; Mutation; Organelle Biogenesis; Oxidative Stress; Phosphatidylinositol 3-Kinases; Phosphorylation; Proteomics; Ribosomes; RNA Polymerase I; RNA Precursors; RNA Processing, Post-Transcriptional; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Sirolimus; Triazoles | 2017 |
A paradigm of endothelium-protective and stent-free anti-restenotic therapy using biomimetic nanoclusters.
Topics: Animals; Azepines; Biomimetic Materials; Carotid Arteries; Carotid Artery Injuries; Coronary Restenosis; Drug-Eluting Stents; Endothelium, Vascular; Humans; Male; Nanoparticles; Neointima; Rats, Sprague-Dawley; Sirolimus; Triazoles | 2018 |
Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study.
Topics: Adult; Aged; Antifungal Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Nitriles; Pyridines; Retrospective Studies; Sirolimus; Tacrolimus; Transplantation, Homologous; Triazoles; Young Adult | 2019 |
Synthesis and anticancer activity of novel rapamycin C-28 containing triazole moiety compounds.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Sirolimus; Structure-Activity Relationship; TOR Serine-Threonine Kinases; Triazoles; Tumor Cells, Cultured | 2018 |
Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Azepines; Carcinogenesis; Cell Line, Tumor; Colorectal Neoplasms; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Humans; Phosphodiesterase 4 Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Resveratrol; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2019 |
In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales.
Topics: Antifungal Agents; Cyclosporine; Immunosuppressive Agents; Microbial Sensitivity Tests; Mucorales; Mucormycosis; Nitriles; Pyridines; Sirolimus; Tacrolimus; Triazoles | 2019 |
Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Topics: Acetanilides; Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Down-Regulation; Drug Synergism; Eukaryotic Initiation Factor-4E; G1 Phase Cell Cycle Checkpoints; Heterocyclic Compounds, 3-Ring; Humans; N-Myc Proto-Oncogene Protein; Neuroblastoma; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Spheroids, Cellular; TOR Serine-Threonine Kinases; Transcription Factors; Triazoles | 2021 |
Topics: Antifungal Agents; Aspergillus; Azoles; Candida; Candida albicans; Drug Resistance, Fungal; Exophiala; Fungi; Humans; Itraconazole; Microbial Sensitivity Tests; Morpholines; Sirolimus; TOR Serine-Threonine Kinases; Triazoles; Voriconazole | 2022 |